Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemocoagulase is an enzyme-based hemostatic agent derived from snake venom (notably Bothrops species). It is used to control and prevent bleeding in a variety of clinical settings including surgical procedures (cardiac surgery, dental operations), traumatic injuries, gynecological and gastrointestinal hemorrhages. Hemocoagulase acts by accelerating the blood coagulation process through thrombin- and thromboplastin-like activity. Specifically, it catalyzes the conversion of fibrinogen to fibrin by cleaving the α-subunit of fibrinogen and promoting polymerization into insoluble fibrin fibers via factor XIII activation. This results in rapid clot formation that helps arrest bleeding and promote wound healing. The drug can be administered intravenously or topically depending on clinical need[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hemocoagulase.